Active Biotech AB (publ)

Kvartalsrapporter

Visar 1 grupper

  1. Kvartalsrapport Q1 2026

    ENSV
    →

    Financial Performance

    • Operating loss for the period amounted to SEK -8.6 M (vs -11.2 M in Q1 2025).
    • Cash and cash equivalents at the end of the period amounted to SEK 53.3 M (vs 65.1 M at year-end 2025).
    • Research and development expenses amounted to SEK 5.8 M (vs 8.2 M in Q1 2025).
    • Administrative expenses amounted to SEK 2.8 M (vs 3.0 M in Q1…

    Öppna rapport